D-0876-2026 Class II Ongoing
FDA drug recall D-0876-2026 was initiated by Par Health USA, LLC on Sep 8, 2026 and is designated Class II. Reason for recall: Crystallization The recall status is ongoing. Affected quantity: 154210 bottles.
Recall details
- Product Type
- Drugs
- Report Date
- Oct 7, 2026
- Initiation Date
- Sep 8, 2026
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 154210 bottles
Product description
Buprenorphine Hydrochloride, Injection 0.3 mg/mL, Rx Only, 5 x 1 mL Single Dose Vials, Manufactured for: Endo USA, Malvern, PA, NDC 42023-179-05
Reason for recall
Crystallization
Distribution pattern
U.S. Nationwide
Code information
Lot#:83912, Exp Date 10/2026 Lot#:84234, Exp Date 11/2026 Lot#:84990, Exp Date 11/2026 Lot#:85003, Exp Date 12/2026 Lot#:86443, Exp Date 01/2027 Lot#:89909, Exp Date 05/2027
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0876-2026
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026